Revolution Medicines Surges 140% in 2026: Still Worth Buying?
Revolution Medicines has been one of biotech's hottest trades this year. Here's whether the rally still has legs.
Revolution Medicines has been an absolute rocket ship in 2026, posting a nearly 140% gain that's turned heads across the biotech sector. That kind of move in a single year demands attention — but it also demands a hard question: are you chasing, or is there still real upside left?
Biotech stocks with this kind of momentum tend to split traders right down the middle. Bulls see a pipeline story that the market is finally pricing correctly. Bears see an overheated chart begging for a pullback. The truth is usually somewhere in between, but in high-conviction biotech plays, the trend can run longer than skeptics expect.
Read more Collateral Quality Will Determine the Stablecoin Winners →
What makes Revolution Medicines worth watching isn't just the price action — it's the underlying thesis. RAS-targeted therapies have long been considered one of oncology's toughest nuts to crack, and any company making credible progress in that space commands a premium. The stock's surge suggests Wall Street is buying the science, not just the story.
That said, a 140% move compresses your margin of safety fast. If you missed the initial leg, sizing and entry discipline matter more than ever. Volatile biotech names can give back gains just as aggressively as they stack them, especially if clinical data disappoints or macro sentiment shifts against risk assets.
The smarter play here isn't blind momentum chasing — it's understanding exactly what catalysts remain on the calendar and whether the current valuation prices them in fairly. Do your homework before you pull the trigger. Continue reading at Yahoo Finance.
